Bronchiolitis and bronchial disorders in interstitial lung disease

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 5, 2011, Pages 316-324

  Pappas, Konstantinos ^a  

^a Venizeleio Pananeio General Hospital   (Greece)

Author keywords

Granulomatous lung disease; sarcoid airway involvement; secondary bronchiolar disorders; small airway disease; smoking related interstitial lung disease

Indexed keywords

BRONCHIOLITIS; BRONCHUS DISEASE; CIGARETTE SMOKING; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INFLAMMATORY DISEASE; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG FIBROSIS; LUNG SARCOIDOSIS; LYMPHANGIOLEIOMYOMATOSIS; PATHOGENESIS; REVIEW;

BIOPSY; BRONCHIAL DISEASES; BRONCHIOLITIS; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80051793117     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328349ae94     Document Type: Review

References (48)

1. Allen TC. Small airways disease. Surg Pathol Clin 2010;3:171-186.
2. Allen TC. Pathology of small airways disease. Arch Pathol Lab Med 2010;134:702-718. This review provides an inclusive description of bronchiolar disorders, either primary or secondary to pulmonary or systemic diseases, along with their distinct histological features.
3. Churg A, Muller NL, Wright JL Respiratory bronchiolitis/interstitial lung disease: fibrosis, pulmonary function, and evolving concepts. Arch Pathol Lab Med 2010;134:27-32. This study establishes a new functional definition of RB-ILD to distinguish it from pure respiratory bronchiolitis and cases of centrilobular emphysema accompanied by interstitial fibrosis.
4. Tazelaar HD, Wright JL, Churg A. Desquamative interstitial pneumonia. Histopathology 2011;58:509-516. This review includes a comprehensive presentation of histology, pathogenesis, differential diagnosis and prognosis of DIP.
5. Ishii H, Iwata A, Oka H, et al. Elevated serum levels of lysozyme in desquamative interstitial pneumonia. Intern Med 2010;49:847-851.
6. Beasley MB. Smoking-related small airway disease-a review and update. Adv Anat Pathol 2010;17:270-276. This review provides the spectrum of histologic findings of small airways in the context of cigarette smoking, differentiating between the pathogenetic mechanisms of disease progression in the large and small airways.
7. Chung JH, Kanne JP. Smoking-related interstitial lung diseases. Semin Roentgenol 2010;45:29-35.
8. Prasse A, Stahl M, Schulz G, et al. Essential role of osteopontin in smokingrelated interstitial lung diseases. Am J Pathol 2009;174:1683-1691.
9. Katzenstein AL, Mukhopadhyay S, Zanardi C, Dexter E. Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. Hum Pathol 2010;41:316-325. This study highlights the surprisingly frequent and often severe interstitial fibrosis encountered in cigarette smokers and points out its distinctive features from specific forms of pulmonary fibrosis, mainly UIP.
10. Wright JL, Tazelaar HD, Churg A. Fibrosis with emphysema. Histopathology 2011;58:517-524.
11. Zhang X, Travis WD. Pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2010;134:1823-1828. This is an updated comprehensive review on the pathogenesis, pathologic features, diagnosis and established and evolving treatments of LAM.
12. Torre O, Harari S. The diagnosis of cystic lung diseases: a role for bronch-oalveolar lavage and transbronchial biopsy? Respir Med 2010;104(Suppl 1):S81-S85. This study clarifies the diagnostic yield of less invasive procedures (BALand TBB) in PLCH and LAM.
13. Mukhopadhyay S, Eckardt SM, Scalzetti EM. Diagnosis of pulmonary Langerhans cell histiocytosis by CT-guided core biopsy of lung: a report of three cases. Thorax 2010;65:833-835.
14. Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010;138:674-681. This study identifies serum VEGF-D level as a specific diagnostic marker for LAM in the appropriate clinical setting (women of childbearing age, cystic lung disease on HRCT), eliminating the necessity for lung biopsy.
15. Martignoni G, Pea M, Reghellin D, et al. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. Arch Pathol Lab Med 2010;134:33-40.
16. Odajima N, Betsuyaku T, Yoshida T, et al. High levels of extracellular matrix metalloproteinase inducer are expressed in lymphangioleiomyomatosis. Hum Pathol 2010;41:935-943. This study discloses the increased expression of extracellular matrix metalloproteinase inducer in LAM lesions and speculates a pathogenetic role of it in LAM cells dissemination and/or extracellular matrix destruction.
17. Kristof AS. mTOR signaling in lymphangioleiomyomatosis. Lymphat Res Biol 2010;8:33-42.
18. Pacheco-Rodriguez G, Moss J. The role of chemokines in migration of metastatic-l ike lymphangioleiomyomatosis cells. Crit Rev Immunol 2010;30:387-394.
19. Seyama K, Kumasaka T, Kurihara M, et al. Lymphangioleiomyomatosis: a disease involving the lymphatic system. Lymphat Res Biol 2010;8:21-31.
20. Glasgow CG, Steagall WK, Taveira-Dasilva A, et al. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med 2010;104(Suppl 1):S45-S58. This study reviews the recent scientific knowledge about the molecular and biologic properties of LAM and recapitulates potential targeted therapies (hormonal intervention, mTOR inhibition, MMP inhibition, metastatic properties of LAM cells), raising questions about their application without distinction.
21. Lacher MD, Pincheira R, Zhu Z, et al. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis. Oncogene 2010;29:6543-6556.
22. Johnson SR. The ERS guidelines for LAM: trying a rational approach to a rare disease. Respir Med 2010;104(Suppl 1):S33-S41. This study attempts a standardization of diagnostic criteria aiming at the improvement both of management and scientific research on LAM.
23. Drakopanagiotakis F, Paschalaki K, Abu-Hijleh M, et al. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response and prognosis. Chest 2011;139:893-900. This study collates the main clinical, radiographic and prognostic features of a series of 61 patients with COP or secondary OP, highlighting the similarities and the minor differences with prognostic implications between them.
24. Jara-Palomares L, Gomez-Izquierdo L, Gonzalez-Vergara D, et al. Utility of high-resolution computed tomography and BAL in cryptogenic organizing pneumonia. Respir Med 2010;104:1706-1711. This study establishes the diagnostic role of thoracic HRCT and BAL for patients with COP, for whom histological confirmation is elusive.
25. Ye Q, Dai H, Sarria R, et al. Increased expression of tumor necrosis factor receptors in cryptogenic organizing pneumonia. Respir Med 2011;105:292-297. This study shows an enhanced expression of TNF receptors and Fas on BAL cells in COP, consistent with aTh1 cytokine driven inflammation, in contrast to the Th2 immune response in IPF, opening a new scientific area for investigation and therapeutic trials.
26. Lee JW, Lee KS, Lee HY, et al. Cryptogenic organizing pneumonia: serial highresolution CT findings in 22 patients. AJR Am J Roentgenol 2010;195:916-922.
27. Yoo JW, Song JW, Jang SJ, et al. Comparison between cryptogenic organizing pneumonia and connective tissue disease-related organizing pneumonia. Rheumatology (Oxford) 2011;50:932-938.
28. Jonigk D, Theophile K, Hussein K, et al. Obliterative airway remodelling in transplanted and nontransplanted lungs. Virchows Arch 2010;457:369-380. This study underlines the shared features of cellularity and protein expression of the airway fibrosis in chronically rejected allografts and chronically failing, nontransplanted lungs.
29. Figueira de Mello GC, Ribeiro Carvalho CR, Adib Kairalla R, et al. Small airway remodeling in idiopathic interstitial pneumonias: a pathological study. Respiration 2010;79:322-332. This study quantitatively analyzes the significant inflammatory and structural alterations of the small airways in the context of UIP and NSIP and speculates on a pathogenetic role of bronchiolar epithelium in the lung-remodeling events occurring in idiopathic interstitial pneumonias based on the increased immunohistochemical expression of MMP-9 and MMP-7 in small airways.
30. Furuhashi K, Suda T, Nakamura Y, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med 2010;104:1204-1210. This study reveals the enhanced expression of the glycoprotein YKL-40 in bronchiolar epithelium of patients with IPF and speculates on its potential pathogenetic role in lung-remodeling and fibrosis, in parallel to airway remodeling in asthmatic patients.
31. Pfaff EM, Becker S, Gunther A, Konigshoff M. Dickkopf proteins influence lung epithelial cell proliferation in idiopathic pulmonary fibrosis. Eur Respir J 2011;37:79-87. This study reveals enhanced expression of Dickkopf proteins in the bronchoalveolar lumen of the IPF lung, demonstrates their impact on epithelial cell proliferation, and recommends them as a potential therapeutic target for IPF.
32. Fiore VF, Lofton MC, Roser-Page S, et al. Polyketal microparticles for therapeutic delivery to the lung. Biomaterials 2010;31:810-817.
33. Guinee DG Jr. Update on nonneoplastic pulmonary lymphoproliferative disorders and related entities. Arch Pathol Lab Med 2010;134:691-701.
34. Baughman RP, Lower EE, Tami T. Upper airway 4: sarcoidosis of the upper respiratory tract (SURT). Thorax 2010;65:181-186. This study provides a comprehensive review of airway manifestations in sarcoidosis, focusing on the differential diagnosis from Wegener granulomatosis, along with a therapeutic algorithm.
35. Polychronopoulos VS, Prakash UB. Airway involvement in sarcoidosis. Chest 2009;136:1371-1380.
36. Nishino M, Washko GR, Hatabu H. Volumetric expiratory HRCT of the lung: clinical applications. Radiol Clin North Am 2010;48:177-183. This study reemphasizes the diagnostic role of volumetric expiratory HRCT of the lung for the evaluation of ILDs with airway involvement and points out the implication of standardization and postprocessing of quantified imaging data to future clinical medical practice.
37. Mukhopadhyay S, Gal AA. Granulomatous lung disease: an approach to the differential diagnosis. Arch Pathol Lab Med 2010;134:667-690. A study dedicated to the differential histologic features of the granulomatous lung diseases, including the infectious ones, with supplementary practical tips to obtain a specific diagnosis.
38. Rahman NA, Fruchter O, Shitrit D, et al. Flexible bronchoscopic management of benign tracheal stenosis: long term follow-up of 115 patients. J Cardiothorac Surg 2010;5:2. This srudy reviews the flexible bronchoscope-based modalities in treating benign tracheal stenosis from various etiologies and introduces the use of high dose rate endobronchial brachytherapy to prevent and treat granulation tissue formation, particularly following a metal stent placement.
39. Teo F, Anantham D, Feller-Kopman D, Ernst A. Bronchoscopic management of sarcoidosis related bronchial stenosis with adjunctive topical mitomycin C. Ann Thorac Surg 2010;89:2005-2007.
40. Hirschmann JV, Pipavath SN, Godwin JD. Hypersensitivity pneumonitis: a historical, clinical, and radiologic review. Radiographics 2009;29:1921-1938.
41. Reghellin D, Poletti V, Tomassett S, et al. Cathepsin-K is a sensitive immunohistochemical marker for detection of micro-granulomas in hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis 2010;27:57-63. This study introduces cathepsin-K as a sensitive immunohistochemical marker for quantitative evaluation of micro-granulomatous reactions in all granulomatous interstitial lung diseases, particularly in chronic HSP.
42. Jinta T, Miyazaki Y, Kishi M, et al. The pathogenesis of chronic hypersensitivity pneumonitis in common with idiopathic pulmonary fibrosis: expression of apoptotic markers. Am J Clin Pathol 2010;134:613-620. This study demonstrates through immunohistochemical investigations the pathogenetic role of apoptotic epithelial cells in chronic HSP, as well as the development of a UIP-like fibrotic pattern.
43. Verma H, Nicholson AG, Kerr KM, et al. Alveolar proteinosis with hypersensitivity pneumonitis: a new clinical phenotype. Respirology 2010;15:1197-1202. This study describes the coexistence of PAP and HSP in five patients and discusses possible linkages between these two distinct pathologies.
44. Beasley MB. The pathologist's approach to acute lung injury. Arch Pathol Lab Med 2010;134:719-727. This study compares AFOP to the many histologic patterns associated with a clinical presentation of acute lung injury, focusing on the importance of clinicopathologic correlation and the limitations of biopsy specimens in elucidating the etiology.
45. Hariri LP, Unizony S, Stone J, et al. Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: a case report and review of the literature. Pathol Int 2010;60:755-759.
46. Heo JY, Song JY, Noh JY, et al. Acute fibrinous and organizing pneumonia in a patient with HIV infection and Pneumocystis jiroveci pneumonia. Respirology 2010;15:1259-1261.
47. Sundaram B, Chughtai AR, Kazerooni EA. Multidetector high-resolution computed tomography of the lungs: protocols and applications. J Thorac Imaging 2010;25:125-141.
48. Devakonda A, Raoof S, Sung A, et al. Bronchiolar disorders: a clinicalradiological diagnostic algorithm. Chest 2010;137:938-951. This study provides a stepwise diagnostic algorithm to bronchiolar disorders, focusing on the critical role of HRCT scanning and the main distinct imaging patterns.